1) Strategic Review Conclusion and Focus on Growth - The Board concluded a strategic review, deciding against selling CooperSurgical, citing a disconnect between intrinsic value and offers received. - Insights gained from the review will enhance shareholder value through a focus on organic growth and disciplined capital allocation, including share repurchases. - Management is committed to driving long-term shareholder value and remains open to future strategic alternatives.

2) Financial Performance and Segment Results - Consolidated revenue for Q3 2026 was $1.066 billion, up approximately 1% YoY; CooperVision revenue was $717 million, flat YoY, primarily due to U.S. channel inventory reductions. - CooperSurgical revenue increased 3% YoY to $349 million, with fertility segment growth of 5% to $141 million. - Non-GAAP EPS rose 4% to $1.15, marking the 11th consecutive quarter of exceeding earnings expectations.

3) Challenges and Inventory Management - CooperVision faced challenges due to proactive U.S. channel inventory reductions, which are expected to impact Q4 results but are aimed at establishing a healthier channel for future growth. - The company anticipates similar inventory reduction impacts in Q4, with underlying demand remaining healthy, evidenced by mid-single-digit consumption growth. - The management has taken steps to ring-fence inventory issues, ensuring they do not extend into fiscal 2027.

4) Operational Initiatives and Product Development - Investments are being made in expanded sales coverage, marketing programs, and enhanced commercial execution capabilities, including AI-driven tools. - The MyDay franchise continues to perform well, with double-digit growth in EMEA and consumption growth in the Americas, supported by new product launches. - CooperSurgical is focusing on fertility growth, with ongoing investments in R&D and a strong pipeline, particularly in genomics.

5) Guidance and Outlook for Investors - For Q4, CooperVision revenue is expected to be between $692 million and $706 million, reflecting a decline of 2% to flat organically. - CooperSurgical revenue is projected to be between $364 million and $374 million, indicating organic growth of 4% to 6%. - Guidance for fiscal 2027 remains uncertain, with expectations of a higher effective tax rate impacting future earnings.

Bottom line: CooperCompanies is navigating through a challenging quarter with proactive inventory management and strategic investments aimed at long-term growth. While short-term performance may be impacted, the focus on enhancing operational efficiency and product innovation positions the company for recovery and potential growth in fiscal 2027, making it a compelling consideration for shareholders.